[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR20020008268A - Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois - Google Patents

Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois Download PDF

Info

Publication number
KR20020008268A
KR20020008268A KR1020000041726A KR20000041726A KR20020008268A KR 20020008268 A KR20020008268 A KR 20020008268A KR 1020000041726 A KR1020000041726 A KR 1020000041726A KR 20000041726 A KR20000041726 A KR 20000041726A KR 20020008268 A KR20020008268 A KR 20020008268A
Authority
KR
South Korea
Prior art keywords
extract
testosterone
alpha
reductase
active ingredient
Prior art date
Application number
KR1020000041726A
Other languages
Korean (ko)
Inventor
윤인병
황성록
장석윤
Original Assignee
성재갑
주식회사 엘지씨아이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 엘지씨아이 filed Critical 성재갑
Priority to KR1020000041726A priority Critical patent/KR20020008268A/en
Publication of KR20020008268A publication Critical patent/KR20020008268A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/22Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: Provided is testosterone 5 alpha-reductase inhibitors containing extracts of Galla Rhois as an active ingredient, which inhibitor can be useful for therapeutic agents in depilation, pimple, benign prostatic hyperplasia and the like. CONSTITUTION: The testosterone 5 alpha-reductase inhibitor contains the extract of Galla Rhois as an active ingredient. A therapeutic agent in depilation is characterized by containing 0.001-10 wt.% of the extract of Galla Rhois as an active ingredient, which extract inhibits testosterone 5 alpha-reductase.

Description

오배자 추출물을 함유하는 테스토스테론 5알파-리덕타아제 저해제{Testosterone 5 alpha-reductase inhibitors containing extracts of Galla Rhois}Testosterone 5 alpha-reductase inhibitors containing extracts of Galla Rhois

본 발명은 전립선 비대증, 여드름, 남성형 탈모증의 치료에 사용될 수 있는 새로운 테스토스테론 5알파-리덕타아제 저해제에 관한 것이다. 보다 구체적으로, 본 발명은 활성성분으로써 오배자의 추출물을 함유하는 테스토스테론 5알파-리덕타아제 저해제에 관한 것이다.The present invention relates to novel testosterone 5 alpha-reductase inhibitors that can be used for the treatment of enlarged prostate, acne, and alopecia areata. More specifically, the present invention relates to a testosterone 5 alpha-reductase inhibitor containing an extract of the gall bladder as an active ingredient.

테스토스테론 5알파-리덕타아제는 전립선, 진피층, 피지선, 모낭 등에서 발견되는 효소로써 남성 호르몬인 테스토스테론을 활성형인 디하이드로테스토스테론(dihydrotestosterone, DHT) 으로 전환시키는 작용을 한다. 그런데, 전립선 비대증 환자의 조직에서는 정상 전립선 조직과 비교해서 디하이드로테스토스테론 함량이 유의하게 높은 것이 알려져 있으며 또한 디하이드로테스토스테론은 모낭 주변의 에너지 생성의 저하와 단백질 합성의 억제를 야기하여 모모세포의 세포 증식을 억제하고 탈모를 일으키는 단백질을 유도하여 남성형 탈모증을 일으키는 주요 유발인자 중 하나로 알려져 있다. 더 나아가 피지세포에서는 피지의과잉 생성을 유발하기도 하여 여드름의 발생, 악화와 지루성 피부염 등의 질환에도 관여하고 있는 것이 근래의 연구에서 밝혀져 있다. 따라서, 이 테스토스테론 5알파-리덕타아제의 작용을 저해하여 조직 중의 디하이드로테스토스테론의 생성을 억제하는 것이 상기 질환을 효과적으로 예방 및 치료할 수 있는 방법이 될 수 있다. 이러한 저해제의 일부는 전립선 비대증의 치료제와 남성형 탈모 치료약으로 이미 임상 응용 되어 있다. 대표적인 테스토스테론 5알파-리덕타아제 저해제인 Finasteride(MSD ltd.)는 이미 미국에서는 전립선 비대증 치료제 및 남성형 탈모 치료용 처방약으로써 이용되고 있다.Testosterone 5 alpha-reductase is an enzyme found in the prostate, the dermis, sebaceous glands, and hair follicles. It acts to convert testosterone, a male hormone, into active dihydrotestosterone (DHT). However, in the tissues of patients with prostatic hyperplasia, it is known that the content of dihydrotestosterone is significantly higher than that of normal prostate tissue. In addition, dihydrotestosterone causes a decrease in energy production around the hair follicles and inhibition of protein synthesis, thereby inhibiting hair cell proliferation. It is known to be one of the major inducers of male hair loss by inducing proteins that inhibit and cause hair loss. Furthermore, recent studies have shown that sebaceous cells induce excessive production of sebum and are also involved in diseases such as acne, exacerbation and seborrheic dermatitis. Therefore, inhibiting the production of dihydrotestosterone in the tissue by inhibiting the action of this testosterone 5 alpha-reductase may be a method that can effectively prevent and treat the disease. Some of these inhibitors have already been clinically applied to treat prostatic hyperplasia and to treat male hair loss. Finasteride (MSD ltd.), A representative testosterone 5-alpha-reductase inhibitor, has already been used in the United States as a prescription drug for the treatment of enlarged prostate and hair loss.

그렇지만, Finasteride는 성욕 감퇴, 사정량 감소, 발기부전 등의 부작용을 나타내고 있고 여성과 어린이에게는 사용이 금지되는 등 사용대상과 용법에 많은 제약을 가지고 있어 그 효과와 실용성이 적고 사용에 상당한 주의가 필요한 실정이다.However, Finasteride has side effects such as decreased libido, decreased ejaculation and erectile dysfunction, and it is prohibited to use for women and children. It is true.

이에 본 발명은 상기와 같은 문제점을 해결하기 위한 것으로, 본 발명자는 부작용이 없이 테스토스테론 5 알파-리덕타아제를 효과적으로 억제할 수 있는 저해제를 찾기 위해 인체 안전성이 우수한 재료를 선택하여 집중적인 연구를 수행한 결과 오배자의 추출물이 강력한 테스토스테론 5 알파-리덕타아제의 저해활성을 나타냄을 확인하고 본 발명을 완성하였다.Accordingly, the present invention is to solve the above problems, the present inventors conducted an intensive study by selecting a material with excellent human safety in order to find an inhibitor that can effectively inhibit testosterone 5 alpha-reductase without side effects As a result, it was confirmed that the extract of Gallja showed strong inhibitory activity of testosterone 5 alpha-reductase and completed the present invention.

본 발명을 좀더 자세하게 설명하면 다음과 같다.The present invention will be described in more detail as follows.

본 발명에 따르는 오배자 추출물은 테스토스테론 5알파-리덕타아제의 활성에 관련된 증상 등의 예방, 처치를 위한 의약품.화장품 분야의 각종 의약 제제, 화장품 등에 이용될 수 있다. 구체적으로는, 피부용 화장품, 두발의 육모용 화장품, 여드름 예방, 치료제제 등에 이용할 수 있다. 상기 이외에 테스토스테론 5알파-리덕타아제의 작용에 기인한 질환의 예방 또는 치료에 사용될 수 있으며 피부 외용으로 한정된 것은 아니고 경구용, 비경구용제형 모두에 적용가능하며, 또한 사용 목적에 따라 적절한 희석제, 부형제 등을 배합해도 무방하다.The gall bladder extract according to the present invention can be used for various pharmaceutical preparations, cosmetics, and the like for the prevention and treatment of symptoms related to the activity of testosterone 5 alpha-reductase. Specifically, it can be used for cosmetics for skin, cosmetics for hair growth of hair, acne prevention, therapeutic agent and the like. In addition to the above, it can be used for the prevention or treatment of diseases caused by the action of testosterone 5-alpha-reductase, and is not limited to external skin, and can be applied to both oral and parenteral formulations, and also suitable diluents and excipients depending on the purpose of use. You may mix | blend etc.

본 발명의 저해제를 두발의 육모용 화장품에 응용하는 경우 통상의 모발 성장 촉진제에 배합되는 다른 성분, 예를 들면 혈액순환 촉진을 위한 고추틴크, 초산토코페롤, 니코틴산벤질, 모근자극, 세포활성을 위한 당약추출물, 인삼추출물, 홍삼추출물, 의이인추출물, 정향추출물, 히노키티올, 니코틴산아미드, 엘-멘톨, 살균 이나 각질용해를 위한 피록톤올아민, 살리실산, 기타 보습제 등을 함께 사용하여 효과를 증진시킬 수 있다.When the inhibitor of the present invention is applied to hair growth cosmetics, other ingredients blended with conventional hair growth promoters, for example, pepper tink, tocopherol acetate, benzyl nicotinate, hair root stimulation, and glycemic agents for cell activity Extracts, ginseng extract, red ginseng extract, oyster extract, cloves extract, hinokthiol, nicotinic acid amide, el-menthol, pyrotonolamine for sterilization or keratin dissolution, salicylic acid, and other humectants can be used together to enhance the effect.

위와 같이 의약품, 의약부외품, 화장품용 조성물로써 이용한 경우 그 적용량은 조성물의 형태 또는 사용목적에 따라 변동될 수 있기 때문에 한정된 것은 아니지만 일반적으로 1일당 5~10mL정도이다. 구체적으로는, 후술의 실시예에 기재된 방법에 따라 얻어지는 추출물을 0.001~10중량%가 되도록 배합한다. 0.001중량% 미만에서는 본 발명의 효과를 충분히 기대하기 어렵고 10중량%를 초과시 용량에 비례하는 효과를 보이지 못하였고 제형을 유지하기 곤란한 점이 발견되어 조성물 중의 적합한 함량은 0.001~ 10중량% 이다.When used as a composition for pharmaceuticals, quasi-drugs, cosmetics as described above, the application amount is not limited because it may vary depending on the form or purpose of use, but is generally about 5 ~ 10mL per day. Specifically, the extract obtained according to the method described in Examples later is blended so as to be 0.001 to 10% by weight. If it is less than 0.001% by weight, it is difficult to fully expect the effect of the present invention, and when it exceeds 10% by weight, it is not found to be proportional to the dose and difficult to maintain the dosage form.

상기에서 언급한 바와 같은 액상의 조성물을 제조하여 시험한 결과 테스토스테론 5알파-리덕타아제 억제 시험에서 양호한 효과를 나타내었고, 모발 성장 유효성 평가 시험, 동물을 이용한 시험 및 탈모증이 있는 사람을 대상으로 한 임상 시험에서 피부 발적 등의 부작용이 전혀 나타나지 않으면서 모발 성장 촉진 효과가 우수한 것으로 평가되었다.As a result of preparing and testing the liquid composition as mentioned above, the test result showed a good effect in the testosterone 5 alpha-reductase inhibition test, and the hair growth efficacy test, the animal test, and the alopecia In clinical trials, it was evaluated that the hair growth promoting effect was excellent without any side effects such as skin redness.

이하, 본 발명의 구체적인 구성과 작용을 참고예, 실험예 및 실시예에 의거하여 더욱 상세하게 설명한다. 그러나, 본 발명은 하기의 예에 국한되지 않는다. 하기 표에서 별다른 언급이 없는 한 단위는 중량%이다.Hereinafter, the specific configuration and operation of the present invention will be described in more detail on the basis of reference examples, experimental examples and examples. However, the present invention is not limited to the following examples. Unless otherwise stated in the following table, the unit is% by weight.

본 발명에 사용된 오배자의 학명은 갈라 로이스(Galla Rhois)이며 루스 자포니카(Rhus japonica L., 옻나무과 Anacardiaceae)의 어린 가지 자상에 오배자 진딧물(Melaphis chinensis B., 솜진딧물과 Erilosomatidae)의 유충이 자극을 주어 발생한 벌레집으로써 우리나라와 일본, 중국이 산지인 생약이다. 오배자 탄닌이 50~70%, gallic acid 등이 주성분으로 수렴제 및 몰식자산, 파이로갈롤의 제조원료 등으로 사용되고 있다.The scientific name of the gallant used in the present invention is Gala Rhois, and the larvae of the gallant aphid (Melaphis chinensis B., cotton aphid and Erilosomatidae) stimulate the young eggplant stagnation of Rhus japonica L., Anacardiaceae. It is a herbaceous herb that originated in Korea, Japan, and China. The gallnut tannin (50-70%) and gallic acid are used as main ingredients of astringents, molar assets, and raw materials for pyrogallol.

참고예: 오배자 추출물의 제조Reference Example: Preparation of Mellitus Extract

본 발명에 사용된 오배자의 추출방법을 설명하면 다음과 같다.Referring to the extraction method of the five gall used in the present invention.

먼저 건조된 시료에 5~10배량의 추출용매를 첨가한 후 5~7일간 냉침하여 추출하거나 1~5시간 가온 추출하여 얻은 추출물을 여과, 농축 후 동결건조 등의 방법을 통하여 오배자 추출물의 건조 분말을 얻었다. 이때 사용한 추출용매로는 정제수, 메탄올, 에탄올, 프로판올, 부탄올, 글리세롤, 프로필렌 글리콜, 1,3-부틸렌 글리콜, 메틸 아세테이트, 에틸 아세테이트, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 중에서 하나 또는 두 종류 이상의 용매를 혼합하여 추출에 사용하는 것이 바람직하다.First, 5 ~ 10 times the amount of the extraction solvent is added to the dried sample, followed by cold extraction for 5 ~ 7 days, or extract extracted by heating for 1 ~ 5 hours. Got. The extraction solvent used at this time is one or two of purified water, methanol, ethanol, propanol, butanol, glycerol, propylene glycol, 1,3-butylene glycol, methyl acetate, ethyl acetate, benzene, hexane, diethyl ether, dichloromethane It is preferable to mix and use the above solvent for extraction.

실험예 1 : 오배자 추출물의 테스토스테론 5알파-리덕타아제 활성 억제력 평가Experimental Example 1 Evaluation of Testosterone 5 Alpha-Reductase Activity Inhibitory Activity of Mellitus Extract

테스토스테론 5알파-리덕타아제 활성 억제 실험에 사용된 테스토스테론 5알파-리덕타아제는 쥐의 간(adult, Sprague-Dawley, 성숙 수컷 래트(8-10 주령))에서 얻었으며 단백질 정량을 통하여 일정량의 단백질 현탁액을 준비하였다. 또한 일반적인 방법으로 효소반응용액을 준비하였다. 테스토스테론 5알파-리덕타아제의 반응 기질로는 방사선 표지된 테스토스테론(3H testosterone)을 사용하였으며 효소반응용액 : 단백질현탁액 : 오배자추출물 = 70 : 20 : 10의 비율로 2분간 항온조에서 반응시킨 후 반응 용매를 날려보내고 남은 물질을 전개 용매에 녹여 박층크로마토그램(TLC)에 전개하고 전개된 테스토스테론의 양과 디하이드로테스토스테론 양을 덴시토미터(densitometer)를 이용하여 정량 분석하여 테스토스테론 5알파-리덕타아제에 의한 테스토스테론에서 디하이드로테스토스테론으로의 전환율을 측정하였으며 그 결과를 대조군(오배자추출물을 첨가하지 않았을 때의 전환율)과 비교하여 테스토스테론 5알파-리덕타아제 억제율을 평가하였다. 억제율 평가 계산 방법은 아래와 같다.Testosterone 5 alpha-reductase activity was used in the test of inhibition of testosterone 5 alpha-reductase activity. The testosterone 5 alpha-reductase was obtained from rat liver (adult, Sprague-Dawley, mature male rats (8-10 weeks old)). Protein suspensions were prepared. In addition, the enzyme reaction solution was prepared in a general manner. Radiolabeled testosterone ( 3 H testosterone) was used as a reaction substrate of testosterone 5 alpha-reductase, and the reaction was carried out in an incubator for 2 minutes at the ratio of enzyme reaction solution: protein suspension: gallnut extract = 70: 20: 10. Blow off the solvent and dissolve the remaining material in the developing solvent and develop it on the thin layer chromatography (TLC). The conversion of testosterone to dihydrotestosterone was measured and the results were compared with the control (conversion rate without the addition of the gall bladder extract) to evaluate the testosterone 5 alpha-reductase inhibition rate. The inhibition rate calculation method is as follows.

억제율(%) = [(A-B)/A] × 100% Inhibition = [(A-B) / A] × 100

상기식에서,In the above formula,

A = 테스토스테론에서 디하이드로테스토스테론으로의 전환율(추출물 미 첨가시)A = conversion of testosterone to dihydrotestosterone (without extract)

B = 테스토스테론에서 디하이드로테스토스테론으로의 전환율(추출물 첨가시)B = conversion of testosterone to dihydrotestosterone (extract added)

상기의 억제율 계산방법에 의한 실험결과는 아래 표1 과 같다.Experimental results by the above inhibition rate calculation method are shown in Table 1 below.

테스토스테론 5알파-리덕타아제 억제율Testosterone 5 alpha-reductase inhibition rate 오배자 추출물 농도(%)Gallnut Extract Concentration (%) 0.10.1 0.010.01 0.0010.001 0.00010.0001 억제율(%)% Inhibition 100.0%100.0% 100.0%100.0% 67.8%67.8% 35.1%35.1%

상기 표 1의 결과에서 알 수 있듯이 오배자 추출물의 테스토스테론 5알파-리덕타아제에 대한 활성 억제 효과는 명확하다.As can be seen from the results of Table 1, the inhibitory effect on the testosterone 5 alpha-reductase of the gall bladder extract is clear.

실시예1 내지 5 및 비교예 1 내지 2Examples 1-5 and Comparative Examples 1-2

본 발명에 따른 오배자 추출물과 기타 보조성분 등을 사용하여 하기 표 2와 같은 성분 및 비율의 오배자 추출물을 함유하는 액상의 양모제를 제조하였다.Using a gall bladder extract and other auxiliary ingredients according to the present invention to prepare a liquid wool formulation containing a gall bladder extract of the ingredients and ratios shown in Table 2.

액상 양모제의 성분 및 비율Ingredients and proportions of liquid wool 원료명Raw material name 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 실시예 5Example 5 비교예 1Comparative Example 1 비교예 2Comparative Example 2 에탄올ethanol 40.040.0 40.040.0 40.040.0 40.040.0 40.040.0 40.040.0 40.040.0 오배자추출물Gall bladder extract 55 0.010.01 0.10.1 1One 55 -- -- 히노키티올Hinoki Thiol -- 0.030.03 0.030.03 0.030.03 0.030.03 -- 0.030.03 고추틴크Pepper Tink -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 니코틴산벤질Benzyl nicotinate -- 0.020.02 0.020.02 0.020.02 0.020.02 -- 0.020.02 당약추출물Sugar extract -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 인삼추출물Ginseng Extract -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 홍삼추출물Red Ginseng Extract -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 의이인추출물Righteous extract -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 정향추출물Clove Extract -- 0.50.5 0.50.5 0.50.5 0.50.5 -- 0.50.5 초산토코페롤Tocopherol Acetate -- 0.10.1 0.10.1 0.10.1 0.10.1 -- 0.10.1 니코틴산아미드Nicotinic acid amide -- 0.10.1 0.10.1 0.10.1 0.10.1 -- 0.10.1 피록톤올아민Pyrotonolamine -- 0.10.1 0.10.1 0.10.1 0.10.1 -- 0.10.1 살리실산Salicylic acid -- 0.30.3 0.30.3 0.30.3 0.30.3 -- 0.30.3 엘-멘톨L-menthol 0.30.3 0.30.3 0.30.3 0.30.3 0.30.3 0.30.3 0.30.3 트윈20Twin 20 0.50.5 0.50.5 0.50.5 0.50.5 0.50.5 0.50.5 0.50.5 향료Spices 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity 색소Pigment 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity 적량Quantity water 100 중량%가 될 때까지 첨가Add until 100% by weight

실험예 2 : 동물을 이용한 모발 성장 촉진 효과 시험Experimental Example 2 Test of Hair Growth Promotion Effect Using Animals

모발 성장 촉진 효과 시험은 생후 42일 ~ 56일된 마우스(C57BL/6, male)를 사용하여 등 부위의 털을 제거하고 상기 실시예 및 비교예에 대하여 각각 10마리씩 개체당 등부위에 1일 1회, 100마이크로리터를 28일간 도포하였다. 그 결과는 화상분석기를 이용하여 털을 제거한 면적에 대하여 신생모가 자란 면적의 비율을 구하여 비교한 결과를 다음 표 3에 나타내었다.Hair growth promoting effect test was used to remove the hair of the back region using a mouse (C57BL / 6, male) 42 days to 56 days old, and once a day at the dorsal area per subject for each of the 10 Examples and Comparative Examples, 100 microliters were applied for 28 days. The results are shown in Table 3 below by comparing the ratio of the area where the newborn hair was grown with respect to the area from which hair was removed using an image analyzer.

신생모의 성장 면적비Growth area ratio of new mother 구 분division 실시예 1Example 1 실시예 2Example 2 실시예 3Example 3 실시예 4Example 4 실시예 5Example 5 비교예 1Comparative Example 1 면적비(%)Area ratio (%) 58.358.3 69.469.4 73.673.6 78.578.5 82.382.3 36.936.9

상기 표 3의 결과와 같이 오배자 추출물을 함유하는 실시예 1 내지 5의 조성물은 비교예 1과 비교하여 유의하게 높은 모발 성장 촉진 효과를 나타내었고 기타의 보조성분을 추가로 함유하는 경우는 그렇지 않은 경우보다 더 높은 효과를 나타내었다.As shown in Table 3, the composition of Examples 1 to 5 containing the gall bladder extract showed a significantly higher hair growth promoting effect compared to Comparative Example 1, and the case of additionally containing other auxiliary components. Higher effect.

실험예 3 : 모발 성장 촉진 효과 임상시험Experimental Example 3 Clinical Trial of Hair Growth Promoting Effect

상기의 실험에서 확인한 오배자 추출물의 테스토스테론 5알파-리덕타아제에 대한 뛰어난 활성억제효과와 동물 시험에서 나타난 모발 성장 촉진 효과를 임상에서 확인하고자 탈모증이 있는 대상자를 선정하여 그 임상효과를 시험하였다.In order to confirm the superior activity inhibitory effect of testosterone 5 alpha-reductase and the hair growth promoting effect shown in the animal test of the gall extract extracted in the above experiments, the subjects with alopecia were selected and tested.

오배자 추출물을 함유한 실시예 5 및 함유하지 않는 비교예 1을 사용하여 모발 성장 촉진에 관한 임상 효과를 측정하기 위하여 30 ~ 50세까지의 성인 남성 탈모증이 있는 사람 또는 일일 평균 탈모수가 100개 이상인 사람 10명씩을 대상으로 실시하였다.Persons with alopecia of adult male hair loss from 30 to 50 years old or persons with an average number of hair loss of 100 or more per day to determine the clinical effect of promoting hair growth using Example 5 containing the gall bladder extract and Comparative Example 1 not containing Ten people each.

사용 방법은 탈모 부위에 1일 2~3회 수적(약 2ml)을 도포하는 것으로 하고 효과 확인의 정도에 따라 최소 1개월에서 최대 3개월까지 사용하였으며 그 이상의 사용은 효과가 없는 것으로 하였다.The method of use was to apply water droplets (about 2ml) 2 ~ 3 times a day to the hair loss site and used for at least 1 month up to 3 months depending on the degree of effect checking.

효과의 판정은 세발시 일일 평균 탈모량, 육안 판정 소견 및 자각 증상 개선 정도를 표 4의 평가 척도에 따라 5단계로 평가하고, 종합적으로 전반적인 개선도를 상기 평가 척도의 평균으로 하였다. 최종 판정은 종합적인 전반 개선도 3.0점 이상을 유효하다고 하였으며 그 결과는 다음의 표 5에 나타내었다.The determination of the effect was evaluated in five stages according to the evaluation scale of Table 4, and the average daily hair loss, visual judgment, and improvement in subjective symptoms were triturated, and overall improvement was taken as the average of the evaluation scale. The final judgment was that the overall improvement was 3.0 points or more, and the results are shown in Table 5 below.

평가 척도Rating scale 단계 구분Phase division 세발시 탈모량Hair Loss at Tricycle 자각 증상Subjective symptoms 육안 판정Visual judgment 5432154321 현저한 감소중등도 감소경도 감소불변악화(증가)Significant Decrease Moderate Decrease Hardness Decrease 현저한 개선중등도 개선경도 개선불변악화Significant improvement Moderate improvement Hardness improvement Unchanged 현저한 개선중등도 개선경도 개선불변악화Significant improvement Moderate improvement Hardness improvement Unchanged

종합적인 전반 개선도Overall overall improvement 단계 구분Phase division 세발시 탈모량Hair Loss at Tricycle 자각 증상Subjective symptoms 육안 판정Visual judgment 종합 개선도Overall improvement 실시예 5비교예 1Example 5 Comparative Example 1 3.92.43.92.4 3.62.63.62.6 3.62.43.62.4 3.72.53.72.5

상기 표 5의 결과와 같이 오배자 추출물을 함유하는 실시예 5는 비교예 1에 비하여 현저한 개선도를 나타내었으며 사용기간 중 대상자 전원에게서 어떠한 부작용도 발견되지 않아 인체에도 안전한 조성물임을 알 수 있었다.As shown in the results of Table 5, Example 5 containing the gall bladder extract showed a marked improvement compared to Comparative Example 1 and did not find any side effects from all the subjects during the use period was found to be a safe composition to the human body.

다.All.

이상 설명하고 실시예를 통하여 살펴본 바와 같이, 본 발명의 오배자 추출물을 함유하는 테스토스테론 5 알파-리덕타아제 저해제는 강력한 테스토스테론 5 알파-리덕타아제 활성 저해 효과를 갖고 있어 의약품, 의약부외품, 화장품 등의 분야에 있어서 남성형 탈모증 치료제, 항 여드름용 치료제, 전립선 비대증 치료제 등에 유효하게 사용될 수 있다.As described above and described through the examples, the testosterone 5 alpha-reductase inhibitor containing the gall bladder extract of the present invention has a strong testosterone 5 alpha-reductase activity inhibitory effect, such as pharmaceuticals, quasi-drugs, cosmetics, etc. It can be effectively used in the field of androgenetic alopecia treatment, anti-acne treatment, prostatic hypertrophy.

Claims (3)

오배자의 추출물을 유효성분으로 함유하는 테스토스테론 5알파-리덕타아제 저해제.Testosterone 5 alpha-reductase inhibitor containing the extract of the gall bladder as an active ingredient. 유효성분으로써 테스토스테론 5알파-리덕타아제를 억제하는 오배자 추출물 0.001-10중량%를 함유하는 것을 특징으로 하는 남성형 탈모증 치료용 조성물.A composition for the treatment of androgenetic alopecia comprising 0.001-10% by weight of a gall bladder extract that inhibits testosterone 5 alpha-reductase as an active ingredient. 제 2항에 있어서, 히노키티올, 고추틴크, 인삼추출물, 홍삼추출물, 의이인추출물, 당약추출물, 정향추출물, 초산토코페롤, 니코틴산아미드, 니코틴산벤질, 피록톤올아민, 살리실산, 엘-멘톨 중에서 선택되는 1종 또는 2종 이상을 추가로 함유하는 것을 특징으로 하는 남성형 탈모증 치료용 조성물.The method according to claim 2, which is selected from hinokithiol, red pepper tincture, ginseng extract, red ginseng extract, oyster extract, sugar extract, clove extract, tocopherol acetate, nicotinic acid amide, nicotinic acid benzyl, pyroxtonolamine, salicylic acid, and el-menthol. Or a composition for treating androgenetic alopecia, further comprising two or more kinds.
KR1020000041726A 2000-07-20 2000-07-20 Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois KR20020008268A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000041726A KR20020008268A (en) 2000-07-20 2000-07-20 Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000041726A KR20020008268A (en) 2000-07-20 2000-07-20 Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois

Publications (1)

Publication Number Publication Date
KR20020008268A true KR20020008268A (en) 2002-01-30

Family

ID=19679044

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000041726A KR20020008268A (en) 2000-07-20 2000-07-20 Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois

Country Status (1)

Country Link
KR (1) KR20020008268A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040047064A (en) * 2002-11-29 2004-06-05 주식회사 에이치에스티씨 Anti-wrinkle cosmetic composition
KR101142773B1 (en) * 2005-06-22 2012-05-18 주식회사 엘지생활건강 Cosmetic composition for promoting stratum corneum delamination
KR101147486B1 (en) * 2010-04-01 2012-05-21 김현기 Composition for improving recognition comprising Galla rhois extract
KR101287052B1 (en) * 2006-01-10 2013-07-17 주식회사 엘지생활건강 Testosterone 5alpha-reductase inhibitor containing elsholtziae herba extract
CN105232605A (en) * 2015-10-16 2016-01-13 烟台新时代健康产业有限公司 Traditional Chinese medicine compound treating prostatic hyperplasia and preparation and application thereof
KR20160059753A (en) * 2014-11-19 2016-05-27 주식회사 엘지생활건강 Cosmetics compositions for hair strengthening

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040047064A (en) * 2002-11-29 2004-06-05 주식회사 에이치에스티씨 Anti-wrinkle cosmetic composition
KR101142773B1 (en) * 2005-06-22 2012-05-18 주식회사 엘지생활건강 Cosmetic composition for promoting stratum corneum delamination
KR101287052B1 (en) * 2006-01-10 2013-07-17 주식회사 엘지생활건강 Testosterone 5alpha-reductase inhibitor containing elsholtziae herba extract
KR101147486B1 (en) * 2010-04-01 2012-05-21 김현기 Composition for improving recognition comprising Galla rhois extract
KR20160059753A (en) * 2014-11-19 2016-05-27 주식회사 엘지생활건강 Cosmetics compositions for hair strengthening
CN105232605A (en) * 2015-10-16 2016-01-13 烟台新时代健康产业有限公司 Traditional Chinese medicine compound treating prostatic hyperplasia and preparation and application thereof

Similar Documents

Publication Publication Date Title
US8715714B2 (en) Uses of rare earth elements for hair improvement
KR101208736B1 (en) The hair growth compositions containing flavonoids
EP2066289A1 (en) Uses of rare earth elements for hair improvement
KR101287052B1 (en) Testosterone 5alpha-reductase inhibitor containing elsholtziae herba extract
KR100484236B1 (en) Hair Growth Promoting Composition
KR100970126B1 (en) Method of preparing?compositions for preventing depilation and for promoting hair-growing
CN113825493A (en) Composition containing albizzia julibrissin extract
KR101654308B1 (en) Composition for improving hair having effect of depilation prevention and good hair
KR100834108B1 (en) Composition for preventing falling out of the hair and promoting growth of the hair
KR101541470B1 (en) Composition for preventing hair loss or promoting hair growth comprising Ginsenoside F2
KR20020008268A (en) Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois
KR101114307B1 (en) Hair growth agent composition
KR101547758B1 (en) Composition for preventing hair loss and promoting hair growth
KR102528199B1 (en) Composition for preventing hair loss and promoting hair growth
KR20070056207A (en) Testosterone 5alpha-reductase inhibitor containing vitis radix extract
KR101252550B1 (en) Cosmetic composition for protecting sebum secretion on the skin
JP2002080327A (en) Hair grower
US20070207114A1 (en) Hair Growth Agent Composition
KR101886359B1 (en) Composition for promoting hair growth containing saponin extracted from the root of Camellia sinensis
JP2002526395A (en) Use of Bold extract in cosmetic or dermatological products
KR20210104608A (en) Composition for preventing hair loss or promoting hair growth comprising extract pupae of male bees
KR20080011970A (en) Compositions for prevention of hair loss or hair restoration containing extracts of pueraria plants
KR0154648B1 (en) Hair growth and restoration promoter
KR102602321B1 (en) Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract
KR20120046564A (en) Compositions for scalp-care and hair restoration containing extracts of melia azedarach fruits as an effective ingredient

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application